Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05701917 · ClinicalTrials.gov registry record · NA

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

A NA study of Venous Thromboembolism and Deep Venous Thrombosis, sponsored by Inari Medical.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
20
Study locations

NCT05701917: Recruiting NA study of Venous Thromboembolism and Deep Venous Thrombosis, sponsored by Inari Medical.

NCT05701917 is a NA study of Venous Thromboembolism and Deep Venous Thrombosis that is actively recruiting participants, run by Inari Medical. The registered enrollment target is 300 participants, below the 6,290-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05701917, a NA study of Venous Thromboembolism and Deep Venous Thrombosis, is actively recruiting participants, sponsored by Inari Medical.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clinical outcomes through the 6-month follow up visit.

Primary Outcome

1. Occurrence of treatment failure or therapy escalation 2. Assessment of PTS severity, as defined by the Villalta scale

Interventions

  • DEVICE ClotTriever System
  • DRUG Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.

Study Locations (20)

Florida

  • Manatee Memorial Hospital - Bradenton
  • Baptist Health Research Institute - Jacksonville
  • Lakeland Vascular Institute - Lakeland
  • HCA Florida Largo Hospital - Largo
  • Sarasota Memorial Hospital - Sarasota
  • BayCare Health System - Tampa

Michigan

  • McLaren Healthcare - Bay City
  • Henry Ford Health - Detroit
  • MyMichigan Medical Center - Midland

Arizona

  • Honor Health - Scottsdale
  • Pima Heart and Vascular - Tucson

California

  • UCI Medical Center - Orange
  • Vascular and Interventional Specialists of Orange County - Orange

Colorado

  • University Of Colorado - Denver

Connecticut

  • Yale University - New Haven

District of Columbia

  • MedStar Health Research Institution - Washington D.C.

Georgia

  • Memorial Health University Medical Center - Savannah

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2023-01-06
Est. Completion 2027-01-15
Phase NA
Inari Medical

12 total trials

What NCT05701917 shows while recruiting

NCT05701917 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 6,290-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (95% lower).

The record links to 3 conditions, with Venous Thromboembolism appearing as the primary indexed condition, and to 2 interventions - of which ClotTriever System is the first listed.

NCT05701917 names 20 study sites across 11 states, led by Florida, Michigan, Arizona.

Frequently Asked Questions

What is clinical trial NCT05701917 about?

NCT05701917 is a clinical study titled "DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis". This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Mana...

What is the current status of trial NCT05701917?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2023-01-06. Estimated completion is 2027-01-15.

What conditions does trial NCT05701917 study?

This clinical trial studies the following conditions: Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome.

What interventions are being tested in trial NCT05701917?

The interventions under investigation include: ClotTriever System (DEVICE), Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. (DRUG).

Who is sponsoring clinical trial NCT05701917?

This trial is sponsored by Inari Medical, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05701917 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Thromboembolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05701917's enrollment target sits among peer trials

300 29th of 47 higher than 19 of 47 other Venous Thromboembolism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Venous Thromboembolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05701917, the US trial registry maintained by the National Library of Medicine. NCT05701917 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.